Literature DB >> 16857812

Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.

Thomas J Lynch1, Alex A Adjei, Paul A Bunn, Tim G Eisen, Jeffrey Engelman, Glenwood D Goss, Daniel A Haber, John V Heymach, Pasi A Jänne, Bruce E Johnson, David H Johnson, Rogerio C Lilenbaum, Matthew Meyerson, Alan B Sandler, Lecia V Sequist, Jeffrey Settleman, Kwok-Kin Wong, Carol S Hart.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16857812     DOI： 10.1158/1078-0432.CCR-06-1005

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN： 1078-0432            Impact factor:   12.531


× No keyword cloud information.
  19 in total

Review 1.  Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of central nervous system metastases from non-small cell lung cancer: the present and the future.

Authors:  Claudia Proto; Martina Imbimbo; Rosaria Gallucci; Angela Brissa; Diego Signorelli; Milena Vitali; Marianna Macerelli; Giulia Corrao; Monica Ganzinelli; Francesca Gabriella Greco; Marina Chiara Garassino; Giuseppe Lo Russo
Journal:  Transl Lung Cancer Res       Date:  2016-12

2.  Dual inhibition of phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell lung cancer cells by a dietary flavonoid fisetin.

Authors:  Naghma Khan; Farrukh Afaq; Fatima H Khusro; Vaqar Mustafa Adhami; Yewseok Suh; Hasan Mukhtar
Journal:  Int J Cancer       Date:  2011-08-26       Impact factor: 7.396

3.  Chemoprevention Trial Feasibility Using Botanicals in Exceptionally High Risk Populations for Lung Cancer.

Authors:  Nagi B Kumar; Gwendolyn P Quinn; Mark G Alexandrow; Jhanelle Gray; Michael Schell; Steve Sutton; Eric B Haura
Journal:  J Clin Trials       Date:  2014-09

4.  Discovery and Biological Evaluation of Novel Dual EGFR/c-Met Inhibitors.

Authors:  Bálint Szokol; Pál Gyulavári; Ibolya Kurkó; Ferenc Baska; Csaba Szántai-Kis; Zoltán Greff; Zoltán Orfi; István Peták; Kinga Pénzes; Robert Torka; Axel Ullrich; László Orfi; Tibor Vántus; György Kéri
Journal:  ACS Med Chem Lett       Date:  2014-01-30       Impact factor: 4.345

5.  Curcumin: a novel Stat3 pathway inhibitor for chemoprevention of lung cancer.

Authors:  Mark G Alexandrow; Lanxi J Song; Soner Altiok; Jhanelle Gray; Eric B Haura; Nagi B Kumar
Journal:  Eur J Cancer Prev       Date:  2012-09       Impact factor: 2.497

6.  Lung cancer chemoprevention.

Authors:  Robert L Keith
Journal:  Proc Am Thorac Soc       Date:  2012-05

7.  MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents.

Authors:  Weiwen Fan; Zhe Tang; Lihong Yin; Bei Morrison; Said Hafez-Khayyata; Pingfu Fu; Honglian Huang; Rakesh Bagai; Shan Jiang; Adam Kresak; Scott Howell; Amit Vasanji; Chris A Flask; Balazs Halmos; Henry Koon; Patrick C Ma
Journal:  Cancer Res       Date:  2011-05-09       Impact factor: 12.701

Review 8.  Nexus of signaling and endocytosis in oncogenesis driven by non-small cell lung cancer-associated epidermal growth factor receptor mutants.

Authors:  Byung Min Chung; Eric Tom; Neha Zutshi; Timothy Alan Bielecki; Vimla Band; Hamid Band
Journal:  World J Clin Oncol       Date:  2014-12-10

Review 9.  Proteomic contributions to personalized cancer care.

Authors:  John M Koomen; Eric B Haura; Gerold Bepler; Rebecca Sutphen; Elizabeth R Remily-Wood; Kaaron Benson; Mohamad Hussein; Lori A Hazlehurst; Timothy J Yeatman; Lynne T Hildreth; Thomas A Sellers; Paul B Jacobsen; David A Fenstermacher; William S Dalton
Journal:  Mol Cell Proteomics       Date:  2008-07-29       Impact factor: 5.911

Review 10.  Chemoprevention of lung cancer.

Authors:  Robert L Keith
Journal:  Proc Am Thorac Soc       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.